Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 2/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | FPR1 | P21462 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.32 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.32 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.32 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
| ▸ | PIM1 | P11309 | 1/20 | 0.32 |
| ▸ | TNF | P01375 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14648458 | 0.91 | EPHX2 (0.36) | EPHX2HSD11B1TDP1FPR1TSHR | |
| SCHEMBL14175279 | 0.75 | EPHX2 (0.40) | EPHX2FPR1TSHRKDM4EHTT | |
| SCHEMBL14175420 | 0.75 | EPHX2 (0.40) | EPHX2FPR1TSHRKDM4EHTT | |
| SCHEMBL4946433 | 0.73 | ALDH1A1 (0.43) | EPHX2TDP1FPR1TSHRKDM4E | |
| SCHEMBL4951450 | 0.73 | ALDH1A1 (0.43) | EPHX2TDP1FPR1TSHRKDM4E | |
| SCHEMBL29617263 | 0.73 | EPHX2 (0.39) | EPHX2FPR1TSHRKDM4EHTT | |
| SCHEMBL4951371 | 0.73 | MEN1 (0.40) | EPHX2TDP1FPR1TSHRKDM4E | |
| SCHEMBL31756476 | 0.72 | ALDH1A1 (0.42) | EPHX2TDP1FPR1TSHRKDM4E | |
| SCHEMBL14648459 | 0.72 | EPHX2 (0.41) | EPHX2TSHRHTTLMNAALDH1A1 | |
| SCHEMBL30285916 | 0.71 | EPHX2 (0.38) | EPHX2TSHRKDM4EHTTHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9150511-B2 | Process for preparing saxagliptin and its novel intermediates useful in the synthesis thereof | APICORE US LLC (US) | 2015-10-06 | — | — | US | disclosed |
| US-9150511-B2 | Process for preparing saxagliptin and its novel intermediates useful in the synthesis thereof | APICORE US LLC (US) | 2015-10-06 | — | — | US | disclosed |
| US-20140235870-A1 | PROCESS FOR PREPARING SAXAGLIPTIN AND ITS NOVEL INTERMEDIATES USEFUL IN THE SYNTHESIS THEREOF | APICORE, LLC (US) | 2014-08-21 | — | — | US | disclosed |
| US-20140235870-A1 | PROCESS FOR PREPARING SAXAGLIPTIN AND ITS NOVEL INTERMEDIATES USEFUL IN THE SYNTHESIS THEREOF | APICORE, LLC (US) | 2014-08-21 | — | — | US | disclosed |
| US-8748631-B2 | Process for preparing saxagliptin and its novel intermediates useful in the synthesis thereof | APICORE, LLC (US) | 2014-06-10 | — | — | US | disclosed |
| US-8748631-B2 | Process for preparing saxagliptin and its novel intermediates useful in the synthesis thereof | APICORE, LLC (US) | 2014-06-10 | — | — | US | disclosed |
| US-20130023671-A1 | PROCESS FOR PREPARING SAXAGLIPTIN AND ITS NOVEL INTERMEDIATES USEFUL IN THE SYNTHESIS THEREOF | APICORE, LLC (US) | 2013-01-24 | — | — | US | disclosed |
| US-20130023671-A1 | PROCESS FOR PREPARING SAXAGLIPTIN AND ITS NOVEL INTERMEDIATES USEFUL IN THE SYNTHESIS THEREOF | APICORE, LLC (US) | 2013-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023671-A1 | PROCESS FOR PREPARING SAXAGLIPTIN AND ITS NOVEL INTERMEDIATES USEFUL IN THE SYNTHESIS THEREOF | DPP4, DPP3, DPP8 | EPHX2 1686/4885HSD11B1 1415/4885TDP1 4006/4885 |
| US-20140235870-A1 | PROCESS FOR PREPARING SAXAGLIPTIN AND ITS NOVEL INTERMEDIATES USEFUL IN THE SYNTHESIS THEREOF | DPP4, DPP3, DPP8 | EPHX2 1686/4885HSD11B1 1415/4885TDP1 4006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.